Prevention of sudden cardiac death in dialysis patients: A nephrologist's perspective

Dialysis and Transplantation

Volumn 37, Issue 4, 2008, Pages 124-129

  Bleyer, Anthony J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; POTASSIUM; STATIN;

ATTENTION; CARDIOMYOPATHY; CAUSE OF DEATH; CLINICAL TRIAL; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DIALYSATE; DRUG USE; HEART DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; NEPHROLOGIST; OUTCOME ASSESSMENT; POPULATION; PRIORITY JOURNAL; REVIEW; RISK; RISK FACTOR; SUDDEN DEATH;

EID: 54549087712     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: 10.1002/dat.20210     Document Type: Review

References (29)

1. National Institutes of Health: National Institute of Diabetes DaKD. Table H.29. Mortality rates by primary cause of mortality, unadjusted. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the U.S. Bethesda, MD, 2007:H.29.
2. National Institutes of Health, National Institute of Diabetes DaKD. Table H.4. Annual mortality rates: dialysis patients. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease. Bethesda, MD, 2007:H.4.
3. Kannel WB, Gagnon DR, Cupples LA. Epidemiology of sudden coronary death: Population at risk. Can J Cardiol. 1990;6:439-444
4. Bleyer AJ, Russell GB, Satko SG. Sudden and cardiac death rates in hemodialysis patients. Kidney Int. 1999;55:1553-1559.
5. Bleyer AJ, Hartman J, Brannon PC, et al. Characteristics of sudden death in hemodialysis patients. Kidney Int. 2006;69:2268-2273.
6. Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int. 2004;65:2380-2389.
7. Abbott KC, Glanton CW, Trespalacios FC, et al. Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int. 2004;65:597-605.
8. Charytan D, Kuntz RE, Mauri L, DeFilippi C. Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients. Am J Kidney Dis. 2007;49:409-416.
9. Muller J, Kaufmann P, Luepker R, et al. Mechanisms precipitating acute cardiac arrest: Review and recommendations of an NHLBI workshop. Circulation. 1997;96:3233-3239.
10. Selby NM, McIntyre CW. The acute cardiac effects of dialysis. Semin Dial. 2007;20:220-228.
11. Mohi-ud-din K, Bali HK, Banerjee S, Sakhuja V, Jha V. Silent myocardial ischemia and high-grade ventricular arrhythmias on maintenance hemodialysis. Ren Fail. 2005;27:171-175.
12. Singh N, Langer A, Freeman MR, Goldstein MB. Myocardial alterations during hemodialysis: insights from new noninvasive technology. Am J Nephrol. 1994;14:173-181
13. McIntyre CW, Burton JO, Selby NM, et al. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc. 2008;3:19-26.
14. Morrison G, Michelson EL, Brown S, Morganroth J. Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients. Kidney Int. 1980;17:811-819
15. Karnik JA, Young BS, Lew NL, et al. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001;60:350-357
16. Bluzaite I, Brazdzionyte J, Zaliunas R, Rickli H, Ammann P. QT dispersion and heart rate variability in sudden death risk stratification in patients with ischemic heart disease. Medicina. 2006;42:450-454
17. Morris S, Galiatsou E, Stewart G, et al. QT dispersion before and after hemodialysis. J Am Soc Nephrol. 1999;10:160-163.
18. Lorincz I, Matyus J, Zilahi Z, et al. QT dispersion in patients with end-stage renal failure and during hemodialysis. J Am Soc Nephrol. 1999;10:1297-1302.
19. Cupisti A, Galetta F, Caprioli R, et al. Potassium removal increases the QTc Interval dispersion during hemodialysis. Nephron. 1999;82:122-126.
20. Cice G, Ferrara L, Di Benedetto A et al.: Dilated cardiomyopathy in dialysis patients - beneficial efects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol. 2001;37:407-411
21. Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study. Nephrol Dial Transplant. 2006;21:2507-2512.
22. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70:1318-1324.
23. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42:201-208.
24. Kovesdy CP, Regidor DL, Mehrotra R, et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol. 2007;2:999-1007.
25. Parfrey PS, Harnett JD, Barre PE. The natural history of myocardial disease in dialysis patients. J Am Soc Nephrol. 1991;2:2-12
26. Burt RK, Gupta-Burt S, Suki WN, et al. Reversal of left ventricular dysfunction after renal transplantation. Ann Intern Med. 2007;111:635-640.
27. Herzog CQ. Can we prevent sudden cardiac death in dialysis patients. Clin J Am Soc Nephrol. 2007;2:410-412.
28. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-1022.
29. Putcha N, Allon, M. Management of hyperkalemia in dialysis patients. Semin Dial. 2007;20:431-439.